Introduction & Market Context. Gruvaktiebolaget Viscaria (VISC) presented its Q1 2025 results and feasibility study on May 8, 2025, highlighting significant progress in its copper mining project in ...

Gruvaktiebolaget Viscaria (VISC) presented its Q1 2025 results and feasibility study on May 8, 2025, highlighting significant progress in its copper mining project in northern Sweden. The company ...

The results PTC released Monday give a fuller look at a Phase 2 study dubbed PIVOT-HD, which randomized Huntington’s patients to receive either placebo or one of two doses of the company’s drug, ...

The Lilly study exacerbates the pressure on Novo, whose market value has dropped by a third since the start of the year. The Lilly data “looks like it is set to transform the GLP-1 space and raise the ...

Novo Nordisk A/S slumped amid concern that a weight-loss pill from rival Eli Lilly & Co. will steal market share from bestsellers such as its injected blockbuster Ozempic.

Dublin slipped to 17th place for potential investment and development in a ranking of 30 cities across Europe, according to a new study. It dropped from 13th position in the previous report.

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a ...

On Thursday, Agios Pharmaceuticals Inc (NASDAQ:AGIO) released topline results from the global Phase 3 ACTIVATE-KidsT study of mitapivat in children aged 1 to <18 years with PK deficiency who are ...

Development, comparative study, and external validation of a new deep learning model for predicting genome-wide gene expression from histopathology slides.. JCO 42 , 3064-3064 (2024). DOI: 10.1200/JCO ...

The data from a study on mice suggests that DA-1241 — combined with Novo Nordisk A/S’s NVO semaglutide (Wegovy) — improves liver fibrosis. It also demonstrates additive hepatoprotective ...